Abstract
AbstractSnakebite envenoming continues to claim many lives across the globe, necessitating the development of improved therapies. To this end, broadly-neutralizing human monoclonal antibodies may possess advantages over current plasma-derived antivenoms by offering superior safety and high neutralization capacity. Here, we report the establishment of a pipeline based on phage display technology for the discovery and optimization of high affinity broadly-neutralizing human monoclonal antibodies. This approach yielded a recombinant human antibody with superior broadly-neutralizing capacities in vitro and in vivo against different long-chain α-neurotoxins from elapid snakes. This antibody prevents lethality induced by Naja kaouthia whole venom at an unprecedented low molar ratio of one antibody per toxin and prolongs the survival of mice injected with Dendroaspis polylepis or Ophiophagus hannah whole venoms.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference55 articles.
1. Gutiérrez, J. M. et al. Snakebite envenoming. Nat. Rev. Dis. Prim. 3, 1–21 (2017).
2. Pucca, M. B. et al. History of envenoming therapy and current perspectives. Front. Immunol. 10, 1598 (2019).
3. Hamza, M. et al. Clinical management of snakebite envenoming: future perspectives. Toxicon X 11, 100079 (2021).
4. Laustsen, A. H. Handbook of Venoms and Toxins of Reptiles (CRC Press, 2021).
5. Richard, G. et al. In vivo neutralization of α-Cobratoxin with high-affinity Llama single-domain antibodies (VHHs) and a VHH-Fc antibody. PLoS One 8, e69495 (2013).
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献